Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.
Latest website image capture
Clouds background image

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    This update advances the site’s displayed revision version in the page footer (v3.5.2 → v3.5.3) without altering the study record details.
    Difference
    0.1%
    Check dated 2026-04-24T05:49:13.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:07:54.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    Content appears unchanged aside from formatting and layout adjustments. No new or removed study data, eligibility criteria, or outcomes are observed.
    Difference
    0.1%
    Check dated 2026-03-26T04:22:40.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Revision banner updated to v3.5.0, replacing v3.4.3. No changes to the study data or page structure are indicated.
    Difference
    0.1%
    Check dated 2026-03-18T21:01:01.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Revision: v3.4.3 updated in the page footer (replacing v3.4.2).
    Difference
    0.1%
    Check dated 2026-03-11T18:39:00.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    Site update to Revision: v3.4.2; the previous funding notice and Revision: v3.4.1 have been removed.
    Difference
    0.5%
    Check dated 2026-02-11T04:44:14.000Z thumbnail image

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.